Class summary at a glance.

Every drug in the Radiographic Contrast Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 17tracked in Part D
CY24 Part D spend: —combined across class
Total Rx claims: —— unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Air

Brand: MEDICAL AIR · — Part D claims (CY24) · First FDA approval: 1938-10-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Barium Sulfate

Brand: E-Z-Disk · — Part D claims (CY24) · First FDA approval: 1974-06-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide

Brand: Carbon Dioxide Refrigerated · — Part D claims (CY24) · First FDA approval: 1963-01-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide Air

— Part D claims (CY24) · First FDA approval: 2004-02-02

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide Air Mixture

— Part D claims (CY24) · First FDA approval: 1975-01-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide Nitrogen

— Part D claims (CY24) · First FDA approval: 2004-02-02

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide Oxygen

— Part D claims (CY24) · First FDA approval: 1987-01-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide Oxygen Mix

— Part D claims (CY24) · First FDA approval: 1997-10-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Carbon Dioxide-Oxygen-Nitrogen Mixture

— Part D claims (CY24) · First FDA approval: 1966-01-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ethiodized Oil

Brand: LIPIODOL · — Part D claims (CY24) · First FDA approval: 2014-03-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Iodixanol

Brand: Visipaque · — Part D claims (CY24) · First FDA approval: 2002-12-13

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Iohexol

Brand: OMNIPAQUE · — Part D claims (CY24) · First FDA approval: 1985-12-26

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Iomeprol Injection

Brand: IOMERVU · — Part D claims (CY24) · First FDA approval: 2022-07-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Iopamidol

Brand: ISOVUE · — Part D claims (CY24) · First FDA approval: 1985-12-31

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Iopromide

Brand: Ultravist · — Part D claims (CY24) · First FDA approval: 2009-12-30

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ioversol

Brand: Optiray · — Part D claims (CY24) · First FDA approval: 2011-10-17

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Oxygen-Carbon Dioxide Mixture

— Part D claims (CY24) · First FDA approval: 1966-01-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.